Head & face medicine · 2026
Application of fully digital occlusal splints in painful temporomandibular disorders: a randomized controlled clinical study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Jianrong, Yin Weiwei, Ding Shuiqing, Cao Jueling, Ding Xiaolin, Liang Yi, Xiao Jingwen
Аннотация
OBJECTIVE: To evaluate the clinical efficacy of digital occlusal splints in alleviating pain and dysfunction in patients with temporomandibular disorders (TMD) and underlying mechanisms.
METHODS: TMD patients were enrolled and divided into digital and conventional occlusal splint groups (n = 66/group). Clinical outcomes, including visual analog scale (VAS) scores and temporomandibular function indices [Craniomandibular Index (CMI), Dysfunction Index (DI), Palpation Index (PI)], were assessed pre- and post-treatment. Cone-beam computed tomography (CBCT) was used to analyze condylar positional changes and joint space adaptation, while quantitative polymerase chain reaction and enzyme-linked immunosorbent assay measured serum levels of inflammatory markers. Correlations between clinical, structural, and biochemical parameters were examined.
RESULTS: Both groups exhibited significant post-treatment reductions in VAS scores, CMI, DI, and PI (P < 0.05), with the digital group demonstrating superior improvements in VAS, PI, and CMI compared to controls (P < 0.001). CBCT revealed favorable structural adaptations in both groups, though the digital group showed greater enhancements in glenoid fossa depth and medial joint space (P < 0.05). Biochemical analysis confirmed significant decreases in tumor necrosis factor-α (TNF-α), fibroblast growth factor receptor 3 (FGFR3), and nitric oxide synthase 2 (NOS2) levels, with additional reductions in nerve growth factor (NGF) and human leukocyte antigen B (HLA-B) observed exclusively in the digital group (P < 0.05).
CONCLUSION: Digital occlusal splints effectively mitigate TMD-related pain and dysfunction, likely through synergistic mechanisms involving occlusal stabilization, joint structural optimization, and inflammatory modulation. This technology represents a promising precision-based approach for personalized TMD management.
METHODS: TMD patients were enrolled and divided into digital and conventional occlusal splint groups (n = 66/group). Clinical outcomes, including visual analog scale (VAS) scores and temporomandibular function indices [Craniomandibular Index (CMI), Dysfunction Index (DI), Palpation Index (PI)], were assessed pre- and post-treatment. Cone-beam computed tomography (CBCT) was used to analyze condylar positional changes and joint space adaptation, while quantitative polymerase chain reaction and enzyme-linked immunosorbent assay measured serum levels of inflammatory markers. Correlations between clinical, structural, and biochemical parameters were examined.
RESULTS: Both groups exhibited significant post-treatment reductions in VAS scores, CMI, DI, and PI (P < 0.05), with the digital group demonstrating superior improvements in VAS, PI, and CMI compared to controls (P < 0.001). CBCT revealed favorable structural adaptations in both groups, though the digital group showed greater enhancements in glenoid fossa depth and medial joint space (P < 0.05). Biochemical analysis confirmed significant decreases in tumor necrosis factor-α (TNF-α), fibroblast growth factor receptor 3 (FGFR3), and nitric oxide synthase 2 (NOS2) levels, with additional reductions in nerve growth factor (NGF) and human leukocyte antigen B (HLA-B) observed exclusively in the digital group (P < 0.05).
CONCLUSION: Digital occlusal splints effectively mitigate TMD-related pain and dysfunction, likely through synergistic mechanisms involving occlusal stabilization, joint structural optimization, and inflammatory modulation. This technology represents a promising precision-based approach for personalized TMD management.